VRPX: Virpax Pharmaceuticals, Inc. Stock

by  •  • Comments Off on VRPX: Virpax Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 0.91
Enterprise Value ($M) -0.60
Book Value ($M) -0.91
Book Value / Share -0.19
Price / Book -1.00
NCAV ($M) -0.91
NCAV / Share -0.19
Price / NCAV -1.00

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -1.25
Return on Equity (ROE) -6.24

Liquidity (mrq)
Quick Ratio 0.63
Current Ratio 0.63

Balance Sheet (mrq) ($M)
Current Assets 1.56
Assets 1.56
Liabilities 2.47
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -12.08
Net Income -12.07

Cash Flow Statement (mra) ($M)
Cash From Operations -16.71
Cash from Investing 0.00
Cash from Financing 9.08

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-23 13G Intracoastal Capital, Llc 4.99

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-03 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 ☐ TRANSITION REPORT PURSUA
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-10-10 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 ☐ TRAN
2024-10-10 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRAN
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 788,745 3,074,806 25.65
2025-03-06 228,709 1,809,649 12.64
2025-03-05 299,069 1,228,446 24.35
2025-03-04 625,041 2,450,730 25.50

(click for more detail)

Similar Companies
VERU – Veru Inc. VINC – Vincerx Pharma, Inc.
VKTX – Viking Therapeutics, Inc. VSTM – Verastem, Inc.
VTGN – Vistagen Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io